Mofacin

Mofacin Adverse Reactions

moxifloxacin

Manufacturer:

Nang Kuang Pharmaceutical

Distributor:

Symgens

Marketer:

Symgens
Full Prescribing Info
Adverse Reactions
Adverse drug reactions (ADRs) based on all clinical studies with moxifloxacin 400 mg (oral and sequential [IV/oral]/intravenous only administration) sorted by CIOMS III categories of frequency (overall n= 17,951, including n = 4,583 from sequential/intravenous therapy studies; status: May 2010) are listed below: ADRs listed under "common" were observed with a frequency below 3% with the exception of nausea and diarrhea.
ADRs derived from post marketing reports (status: May 2010) are printed in bold italic. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as: common (≥1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000). (See Table 10.)

Click on icon to see table/diagram/image

The following undesirable effects have a higher frequency in the subgroup of IV/oral sequentially treated patients: Common: Increased gamma-glutamyl-transferase.
Uncommon: Ventricular tachyarrhythmias, hypotension, edema, antibiotic associated colitis (in very rare cases associated with life threatening complications), seizures of various clinical manifestations (including grand mal convulsions), hallucination, renal impairment and renal failure (due to especially in elderly with pre-existing renal disorders).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in